Yong Huo1, Stephen W-L Lee2, Jitendra P S Sawhney3, Hyo-Soo Kim4, Rungroj Krittayaphong5, Vo T Nhan6, Angeles Alonso-Garcia7, Ya Ling Han8, Junbo Ge9, Chee Tang Chin10, Tiong K Ong11, Stephen Jan12, Yohji Itoh13, Ana Maria Vega14, Stuart Pocock15. 1. Department of Cardiology, Peking University First Hospital, Beijing, China. 2. Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China. 3. Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, India. 4. Clinical Research Institute, Seoul National University Hospital, Seoul, Korea. 5. Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 6. Department of Medicine, Cho Ray Hospital, Ho Chi Minh City, Vietnam. 7. Cardiovascular Science Research Centre, St. George's University of London, London, United Kingdom. 8. Department of Cardiology, Shenyang Northern Hospital, Shenyang, China. 9. Department of Cardiology, Zhongshan Hospital, Shanghai, China. 10. Department of Cardiology, National Heart Centre Singapore, Singapore and Duke-NUS Graduate Medical School, Singapore. 11. Department of Cardiology, Sarawak General Hospital, Kuching, Malaysia. 12. Health Economics Program, The George Institute for Global Health, University of Sydney, Sydney, Australia. 13. Clinical Science Division, AstraZeneca, Osaka, Japan. 14. Observational Research Centre, Global Medical Affairs, AstraZeneca, Madrid, Spain. 15. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Abstract
BACKGROUND: In-hospital and postdischarge mortality for acute coronary syndromes (ACS) vary across Asia and remain generally poorer than globally. The relationship between real-life antithrombotic management patterns (AMPs) and ACS-related outcomes in Asia is unclear. METHODS: EPICOR Asia (Long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients in Asia) (NCT01361386) is a prospective, multinational, observational study of patients discharged after hospitalization for an ACS, with 2-year follow-up. The aim is to describe short- and long-term (up to 2 years post-index event) AMPs in patients hospitalized for ACS and to record clinical outcomes, healthcare resource use, and self-reported health status. Pre- and in-hospital management, AMPs, and associated outcomes, with particular focus on ischemic and bleeding events, will be recorded during the 2-year follow up. RESULTS: Between June 2011 and May 2012, 13 005 patients were enrolled. From these, 12 922 patients surviving an ACS (6616 with STEMI, 2570 with NSTEMI, and 3736 with UA) were eligible for inclusion from 219 hospitals across 8 countries and regions in Asia: China (n = 8214), Hong Kong (n = 177), India (n = 2468), Malaysia (n = 100), Singapore (n = 93), South Korea (n = 705), Thailand (n = 957), and Vietnam (n = 208). CONCLUSIONS: EPICOR Asia will provide information regarding clinical management and AMPs for ACS patients in Asia. Impact of AMPs on clinical outcomes, healthcare resource use, and self-reported health status both during hospitalization and up to 2 years after discharge will also be described.
BACKGROUND: In-hospital and postdischarge mortality for acute coronary syndromes (ACS) vary across Asia and remain generally poorer than globally. The relationship between real-life antithrombotic management patterns (AMPs) and ACS-related outcomes in Asia is unclear. METHODS: EPICOR Asia (Long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndromepatients in Asia) (NCT01361386) is a prospective, multinational, observational study of patients discharged after hospitalization for an ACS, with 2-year follow-up. The aim is to describe short- and long-term (up to 2 years post-index event) AMPs in patients hospitalized for ACS and to record clinical outcomes, healthcare resource use, and self-reported health status. Pre- and in-hospital management, AMPs, and associated outcomes, with particular focus on ischemic and bleeding events, will be recorded during the 2-year follow up. RESULTS: Between June 2011 and May 2012, 13 005 patients were enrolled. From these, 12 922 patients surviving an ACS (6616 with STEMI, 2570 with NSTEMI, and 3736 with UA) were eligible for inclusion from 219 hospitals across 8 countries and regions in Asia: China (n = 8214), Hong Kong (n = 177), India (n = 2468), Malaysia (n = 100), Singapore (n = 93), South Korea (n = 705), Thailand (n = 957), and Vietnam (n = 208). CONCLUSIONS: EPICOR Asia will provide information regarding clinical management and AMPs for ACS patients in Asia. Impact of AMPs on clinical outcomes, healthcare resource use, and self-reported health status both during hospitalization and up to 2 years after discharge will also be described.
Authors: Héctor Bueno; Xavier Rossello; Stuart Pocock; Frans Van de Werf; Chee Tang Chin; Nicolas Danchin; Stephen W-L Lee; Jesús Medina; Ana Vega; Yong Huo Journal: Clin Res Cardiol Date: 2018-04-16 Impact factor: 5.460
Authors: Yong Huo; Frans Van de Werf; Yaling Han; Xavier Rossello; Stuart J Pocock; Chee Tang Chin; Stephen W-L Lee; Yi Li; Jie Jiang; Ana Maria Vega; Jesús Medina; Héctor Bueno Journal: Am J Cardiovasc Drugs Date: 2021-02-04 Impact factor: 3.571
Authors: Stephen Jan; Stephen W-L Lee; Jitendra P S Sawhney; Tiong K Ong; Chee Tang Chin; Hyo-Soo Kim; Rungroj Krittayaphong; Vo T Nhan; Yohji Itoh; Yong Huo Journal: Bull World Health Organ Date: 2016-01-28 Impact factor: 9.408
Authors: Stephen Jan; Stephen W-L Lee; Jitendra P S Sawhney; Tiong K Ong; Chee Tang Chin; Hyo-Soo Kim; Rungroj Krittayaphong; Vo T Nhan; Stuart J Pocock; Ana M Vega; Nobuya Hayashi; Yong Huo Journal: BMC Cardiovasc Disord Date: 2018-07-04 Impact factor: 2.298
Authors: Bo Zheng; Yong Huo; Stephen W-L Lee; Jitendra P S Sawhney; Hyo-Soo Kim; Rungroj Krittayaphong; Stuart J Pocock; Vo T Nhan; Angeles Alonso Garcia; Chee Tang Chin; Jie Jiang; Stephen Jan; Ana Maria Vega; Nobuya Hayashi; Tiong K Ong Journal: Clin Cardiol Date: 2020-07-02 Impact factor: 2.882